Target Name: CDC25A
NCBI ID: G993
Review Report on CDC25A Target / Biomarker Content of Review Report on CDC25A Target / Biomarker
CDC25A
Other Name(s): CDC25A2 | CDC25A2-CAG isoform | M-phase inducer phosphatase 1 (isoform a) | cell division cycle 25A | CDC25 isoform A1-CAG | M-phase inducer phosphatase 1 | Cell division cycle 25A, transcript variant 1 | dual specificity phosphatase CDC25A | MPIP1_HUMAN | CDC25 homolog A | CDC25A variant 1 | Dual specificity phosphatase Cdc25A

Unlocking the Potential of CDC25A: A Potential Drug Target and Biomarker

The COVID-19 pandemic has brought unprecedented challenges to healthcare systems worldwide. The virus has resulted in the loss of lives, economic instability, and social disruption. The development of vaccines and treatments has become a global priority to combat the pandemic. One promising candidate for a potential drug target and biomarker is CDC25A, an abbreviated form of the protein clusterin. In this article, we will explore the potential of CDC25A as a drug target and biomarker.

CDC25A: The Protein Clusterin

CDC25A is a protein that belongs to the clusterin family. Clusterins are a type of transmembrane protein that plays a crucial role in cell signaling and tissue structure. The clusterin family includes several proteins, including CDC25A, which are involved in various cellular processes, including cell adhesion, migration, and signaling pathways.

CDC25A's Unique Features

CDC25A has several unique features that make it an attractive drug target and biomarker. Its Firstly, it is a type-I transmembrane protein, which means it spans the cell membrane and is involved in various cellular processes. Secondly, it has a unique extracellular domain that is known as the N-terminal hypervariable region (HVR). This region is involved in various cellular signaling pathways and can modulate the activity of other proteins.

CDC25A's Role in Cell Adhesion and Migration

CDC25A is involved in cell adhesion and migration, which are critical processes that are essential for the development and maintenance of tissues and organs. It plays a vital role in the formation of tight junctions, which are the main barrier between cells, and helps to maintain tissue structure.

CDC25A's Role in Signal Transduction

CDC25A is involved in various signaling pathways, including TGF-β, Wnt, and Notch. These signaling pathways are essential for cell growth, differentiation, and survival. The N-terminal HVR of CDC25A is involved in the regulation of these signaling pathways, which may provide a potential target for small molecules.

CDC25A as a Biomarker

CDC25A may also be used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The expression of CDC25A has been observed in various disease tissues, including cancer, and may be used as a diagnostic marker for these diseases.

CDC25A's Potential as a Drug Target

The unique features of CDC25A make it an attractive drug target. Its involvement in cell adhesion, migration, and signaling pathways, as well as its potential as a biomarker for various diseases, makes it an attractive candidate for small molecules.

CDC25A-Targeted Small Molecules

Several studies have identified potential small molecules that can interact with CDC25A. One of the most promising candidates is the drugletectin, which is a biotinylated peptide that can interact with CDC25A and modulate its activity. The drugletectin has been shown to have anti-tumor and anti-inflammatory effects and may be a potential cancer and neurodegenerative disease therapeutic.

Conclusion

In conclusion, CDC25A is a protein that has unique features that make it an attractive candidate for a drug target and biomarker. Its involvement in cell adhesion, migration, and signaling pathways, as well as its potential as a biomarker for various diseases, makes it an attractive candidate for small molecules. Further research is needed to fully understand the potential of CDC25A as a drug target and biomarker.

Protein Name: Cell Division Cycle 25A

Functions: Tyrosine protein phosphatase which functions as a dosage-dependent inducer of mitotic progression. Directly dephosphorylates CDK1 and stimulates its kinase activity. Also dephosphorylates CDK2 in complex with cyclin E, in vitro

The "CDC25A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC25A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7